Medtronic, a global leader in healthcare technology, will share new data for the Prevail™ Drug-Coated Balloon, Evolut™ PRO and PRO+, and Symplicity Spyral™ renal denervation (RDN) system at the upcoming 37th Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. The conference will showcase key data presentations and advancements across its Coronary, Structural Heart and Renal Denervation businesses in the Medtronic Cardiovascular Portfolio..

医疗器械领域的全球领导者美敦力公司将在即将举行的第37届经导管心血管治疗（TCT）科学研讨会上，分享Prevail™药物涂层球囊、Evolut™ PRO和PRO+以及Symplicity Spyral™肾去神经术（RDN）系统的新数据。会议将展示其冠状动脉、结构性心脏病和肾去神经术业务在美敦力心血管产品组合中的关键数据展示和进展。

New evidence demonstrating the real-world usage of

新证据表明了现实世界中的使用情况

Prevail™ coronary paclitaxel drug-coated balloon (DCB)

Prevail™冠状动脉紫杉醇药物涂层球囊（DCB）

in complex populations including diabetic patients

在包括糖尿病患者在内的复杂人群中

Real-World Usage of the Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons for Long Coronary Artery Lesions

与其它当代药物涂层球囊相比，Prevail紫杉醇涂层球囊在长冠状动脉病变中的实际应用

Monday, Oct. 27, 9 a.m. Station 6 | Halls B-C | Exhibition Level | Moscone South | Moscone Center

10月27日星期一，上午9点，6号展厅 | B-C厅 | 展览层 | 莫斯康南馆 | 莫斯康中心

Presenter: Prof. David Erlinge

演讲者：大卫·厄林格教授

New real-world data from Swedish Coronary Angiography and Angioplasty Registry (SCAAR) on the Prevail™ DCB

瑞典冠状动脉造影和血管成形术注册中心 (SCAAR) 关于Prevail™ DCB 的新现实世界数据

1

1

, presented at TCT 2025, will highlight outcomes of Prevail™ paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Prevail DCB) in patients with long lesions, multi-vessel disease and hybrid percutaneous coronary intervention (PCI). Prevail DCB is the only DCB with a CE Mark indication for multivessel disease..

，提交给TCT 2025，将重点展示Prevail™紫杉醇涂层经皮冠状动脉腔内成形术（PTCA）球囊导管（Prevail DCB）在长病变、多支血管疾病和混合经皮冠状动脉介入治疗（PCI）患者中的结果。Prevail DCB是唯一拥有CE标志适应症用于多支血管疾病的DCB。

CAUTION: Prevail is an investigational device in the US. Limited by Federal (US) law to investigational use. Not approved by FDA and not for sale in the US. Prevail DCB received CE mark in 2020, Prevail expanded indications are approved in the EU and UK only.

注意：Prevail 是美国的一种试验性装置。根据美国联邦法律，仅限于试验性使用。未获 FDA 批准，也不在美国销售。Prevail DCB 于 2020 年获得 CE 标志，Prevail 的扩展适应症仅在欧盟和英国获批。

Real-World Usage of the Prevail Paclitaxel-Coated Balloon Compared with Other Contemporary Drug-Coated Balloons for Diabetes Mellitus

糖尿病患者中Prevail紫杉醇涂层球囊与其他当代药物涂层球囊的实际应用比较

Monday, Oct. 27, 10 a.m. Room: Station 6 | Halls B-C | Exhibition Level | Moscone South | Moscone Center

10月27日星期一，上午10点，房间：6号厅 | B-C厅 | 展览层 | 莫斯康南楼 | 莫斯康中心

Presenter: Prof. David Erlinge

主讲人：大卫·埃林格教授

New real-world data from Swedish Coronary Angiography and Angioplasty Registry (SCAAR) on the Prevail™ DCB, presented at TCT 2025, will highlight the safety and effectiveness of Prevail™ paclitaxel-coated percutaneous transluminal coronary angioplasty (PTCA) balloon catheter (Prevail DCB) in diabetic patients.

瑞典冠状动脉造影和血管成形术注册中心 (SCAAR) 提供的关于 Prevail™ DCB 的最新真实世界数据，在 TCT 2025 上公布，将重点展示 Prevail™ 涂有紫杉醇的经皮冠状动脉腔内成形术 (PTCA) 球囊导管（Prevail DCB）在糖尿病患者中的安全性和有效性。

Prevail DCB is the only DCB with a CE Mark indication for diabetic patients..

Prevail DCB是唯一拥有针对糖尿病患者CE标志的DCB。

CAUTION: Prevail is an investigational device in the US. Limited by Federal (US) law to investigational use. Not approved by FDA and not for sale in the US. Prevail DCB received CE mark in 2020, Prevail expanded indications are approved in the EU and U.K. only.

注意：Prevail 是美国的一款试验性设备。根据美国联邦法律，仅限于试验性使用。未经 FDA 批准，也不在美国销售。Prevail DCB 于 2020 年获得 CE 认证，Prevail 的扩展适应症仅在欧盟和英国获批。

Structural Heart and Aortic key data milestones at TCT:

TCT上的结构性心脏和主动脉关键数据里程碑：

Final Global Results from the Optimize PRO Study

Optimize PRO研究的最终全球结果

Structural Scientific Abstracts/Session, Saturday, October 25 at 9:30 am PT. Room: Station 1 | Hall D

结构科学摘要/会议，10月25日星期六上午9:30（太平洋时间）。房间：1号站 | D厅

Presenter: Dr. Steven Yakubov

主持人：史蒂文·雅库博夫博士

The final global results from the Optimize PRO Trial will demonstrate significant improvements in procedural outcomes for transcatheter aortic valve replacement (TAVR). Conducted across 50 global centers with 653 patients, the study evaluated the impact of optimized care pathways and advanced procedural techniques..

Optimize PRO试验的最终全球结果将证明经导管主动脉瓣置换术（TAVR）在手术结果方面的显著改善。该研究在全球50个中心进行，涉及653名患者，评估了优化护理路径和先进手术技术的影响。

Medtronic advances Renal Denervation, showcasing durability and real-world experience

美敦力推进肾去神经术，展示持久性和真实世界经验

Durable Safety and Efficacy of Renal Denervation using the Symplicity Spyral Catheter in Patients Taking Antihypertensive Drugs: Final, 3-Year Results from the SPYRAL HTN-ON MED Randomized Study

使用Symplicity Spyral导管进行肾去神经术在服用抗高血压药物患者中的持久安全性和有效性：SPYRAL HTN-ON MED随机研究的最终3年结果

Featured Clinical Research: October 26, 2:24 pm. Endovascular Spotlight Theater Hall F Presenter: D. Kandzari

特色临床研究：10月26日，下午2点24分。血管内聚焦剧院大厅F，演讲者：D. Kandzari

This featured clinical research will report on the three years of the SPYRAL HTN-ON MED trial, which will look at blood pressure reductions in 24-hour ambulatory and office systolic blood pressure (SBP) compared with sham control in hypertensive patients.

这项特色临床研究将报告SPYRAL HTN-ON MED试验的三年研究结果，该试验将比较高血压患者在24小时动态和诊室收缩压（SBP）与假手术对照组之间的血压降幅。

First Report of the SPYRAL AFFIRM Study: Reduced Home and Office Blood Pressure Following Radiofrequency Renal Denervation in a Large U.S. Cohort of High Cardiovascular Risk Patients

SPYRAL AFFIRM 研究的首次报告：美国大型高心血管风险患者队列中射频肾去神经术后的家庭和诊室血压降低

Featured Clinical Research: October 27, 3:00 pm. Endovascular Spotlight Theater Hall F Presenter: F. Mahfoud

特色临床研究：10月27日，下午3:00。血管内治疗焦点剧场大厅F。演讲者：F. Mahfoud。

Professor Mahfoud’s presentation will add to the breadth of real-world data for Symplicity Spyral as a guideline-recommended treatment for uncontrolled high blood pressure. The SPYRAL AFFIRM study collected additional safety and efficacy data following RDN in high-cardiovascular-risk patient subgroups, predominantly from the US..

马哈福德教授的报告将增加Symplicity Spyral作为指南推荐的难治性高血压治疗手段的实际数据广度。SPYRAL AFFIRM 研究在高心血管风险患者亚组中收集了去肾神经术（RDN）后的额外安全性和有效性数据，这些患者主要来自美国。

Same day discharge with the Symplicity Renal Denervation system: Outcomes from the real world Global Symplicity Registry DEFINE

使用Symplicity肾去神经支配系统当天出院：来自真实世界全球Symplicity注册DEFINE的结果

Oral abstract: Monday, October 27 2:00 p.m. Endovascular Spotlight Theater Halls B-C Presenter: F. Mahfoud

口头摘要：10月27日星期一 下午2:00 血管内焦点剧院 B-C厅 演讲者：F. Mahfoud

This presentation will highlight the safety and effectiveness of same-day discharges following the Symplicity Blood Pressure procedure.

本演示将重点介绍Symplicity血压手术后当天出院的安全性和有效性。

About Medtronic

关于美敦力

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更大胆行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，致力于通过寻找和发现解决方案，勇敢攻克人类面临的最严峻健康问题。我们的使命——减轻病痛、恢复健康、延长生命——凝聚了遍布150多个国家的95,000多名充满热情的员工。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和疗法可治疗70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们广泛的知识、永无止境的好奇心和帮助所有有需要者的愿望，我们提供了创新技术，每秒、每小时、每一天都在改变两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

随着我们推动以洞察力为导向的护理、以人为本的体验以及为我们的世界带来更好的结果，请对我们有更多期待。在我们所做的一切中，我们正在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow us on

并关注我们

LinkedIn

领英

.

。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the U.S. Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力向美国证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果有重大差异。

Contacts:

联系人：

Krystin Hayward Leong

克莉丝汀·海沃德·梁

Public Relations

公共关系

+1-508-261-6512

+1-508-261-6512

Ryan Weispfenning

瑞安·魏斯芬宁

Investor Relations

投资者关系

+1-763-505-4626

+1-763-505-4626

1

1

Prevail DCB is not indicated for hybrid PCI, and drug eluting stents must not be implanted in the vessel segment that has been treated with a Prevail DCB

Prevail DCB 不适用于混合型 PCI，且药物洗脱支架不得植入已经过 Prevail DCB 治疗的血管段。